Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed and Gemcitabine in Advanced NSCLC
NCT00193414Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- May 2005
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed and gemcitabine in non-small cell lung cancer (NSCLC), sponsored by SCRI Development Innovations. Primary endpoint: Overall Response Rate at 18 months. Started May 2005; status: completed.
02
Drugs
pemetrexedgemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00193414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193414.